Tesamorelin: an evidence-first deep dive

This quiz is separate from the lesson so you can finish learning first, then test what you retained.

Lesson checkpoint

Tesamorelin: an evidence-first deep dive checkpoint

This checkpoint tests the lesson you just completed. Passing marks it complete and unlocks the next course step.

Get every question correct to pass.

1. What is tesamorelin's FDA-approved use?

General weight-loss managementReduction of excess abdominal fat in adults with HIV-associated lipodystrophyMuscle gain in healthy adultsTreatment of all forms of fatty liver disease

2. What was the key endpoint in the pivotal tesamorelin trials?

Visceral adipose tissueHair densityTendon strengthMaximum bench press

3. Why doesn't approval for HIV-associated lipodystrophy prove tesamorelin is a general obesity treatment?

Approval applies to a specific population, endpoint and benefit-risk questionApproved drugs can never be studied elsewhereVisceral fat is not measurableOnly animal evidence exists

4. What happened when some participants stopped tesamorelin in extension studies?

Much of the visceral-fat benefit was lostThe benefit became permanently largerNo follow-up was performedBody weight doubled

5. What does a positive liver-fat study mean for the approved indication?

It is useful research but does not automatically expand the approved indicationIt immediately creates a new approvalIt proves tesamorelin treats every liver diseaseIt makes the pivotal trials irrelevant

PThe Pep Report

Educational information only. Not medical advice.

Personalised Guide Safety & info Research Sourcing Guide